The key efficacy endpoint was change from baseline MADRS score. This small-time period analyze found that, compared to intranasal placebo moreover oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant significantly enhanced depressive symptoms immediately after 4 months by a mean difference of four points on the MADRS. The https://fredm777hxk4.bloggerbags.com/profile